This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Carl C. Peck, MD; Peter H. Rheinstein, MD, JD, MS

JAMA. 1990;264(18):2424-2425.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Dr Kessler and Mr Pines¹ present a thoughtful and balanced review of the Food and Drug Administration's (FDA) regulation of prescription drug promotion. In their conclusion, the authors call to mind issues where the need for change is clear and other issues that have long vexed the agency. Mr Pines, a former FDA Associate Commissioner for Public Affairs, is intimately familiar with these issues and has chaired conferences on them in several forums. Many of the presentations from these conferences have been published.^2,3

The article makes some cogent observations. The need to revise the brief summary for use in advertising in a way that makes it readable and more useful is inescapable. The need for governmental oversight of promotional activities involving gifts and other financial inducements to health care providers, such as travel, was made clear in hearings conducted by Sen Edward Kennedy of Massachusetts as early as . . . [Full Text PDF of this Article]

Author Affiliations
From the Center for Drug Evaluation and Research (Dr Peck) and the Office of Health Affairs (Dr Rheinstein), Food and Drug Administration, Rockville, Md.

Footnotes
Reprint requests to Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fisher Ln, HFD-1, Room 13B-45, Rockville, MD 20857 (Dr Peck).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?